All Substitutes
Loading...
Disclaimer
Did you find this information helpful?
Mabtas N 500mg Injection
Prescription Required
Salt Composition : Rituximab
Manufacturer : INTAS PHARMACEUTICALS LTD
Origin of Medicine : India
1 Vial(s) Of 50ml
Introduction to Mabtas N 500mg Injection
Mabtas N 500mg Injection contains the active constituent rituximab. It is used for several different disease conditions in adults. It is used alone or with other medications to treat non-hodgkin’s lymphoma (cancer affecting white blood cells called B-lymphocytes) and chronic lymphocytic leukemia (a most common form of cancer that affects B-cells). It is also indicated to treat moderate-to-severe rheumatoid arthritis (a type of disease where the immune system attacks the body cells of its own joints) in combination with methotrexate in adults. Other uses include granulomatosis with polyangiitis or microscopic polyangiitis (inflammation of blood vessels that mainly affects the lungs and kidneys) in adults and children 2 years of age and older. It is also used to treat moderate to severe pemphigus vulgaris (an autoimmune condition that causes painful blisters on the skin and lining of the mouth, throat, nose, and genitals.
Mabtas N 500mg Injection belongs to the class of medications called anti-CD20 monoclonal antibodies. Do not take this injection if you are allergic to rituximab or any other ingredients of this medicine, have a weak immune system, or have any severe active infection. Inform your physician if you have heart disease, heart failure, or breathing problems before initiating the treatment. Talk with your doctor if you have ever had a hepatitis B infection because in a few cases, the infection may reactivate again and can be severe sometimes. Pregnancy and breastfeeding are not recommended when you are taking this injection.
Common side effects of Mabtas N 500mg Injection include infection of the blood, reduced red blood cells, dizziness, swelling in the face and body, itchy skin, diarrhea, increased sweating, and low or high blood pressure. Use effective contraceptive methods during the treatment and for 12 months after the last dose if you can get pregnant. This medicine may cause severe infusion reactions during or within 24 hours after administration. Inform your physician or healthcare professional if you face any infusion reactions such as increased blood pressure, chest pain, headache, breathing difficulties, vomiting, skin rashes, or throat swelling.
Uses of Mabtas N 500mg Injection
- Non-hodgkin’s lymphoma (NHL)
- Chronic lymphocytic leukemia (CLL)
- Rheumatoid Arthritis
- Granulomatosis with polyangiitis or microscopic polyangiitis
- Pemphigus vulgaris
Therapeutic Effects of Mabtas N 500mg Injection
Mabtas N 500mg Injection is a monoclonal antibody that targets the antigen CD20 expressed on the cell surface of B-lymphocytes (a type of white blood cells). When this medicine binds to the B-cell, it induces cell death in NHL and CLL. The binding action blocks cell activation and growth and causes anticancer effects. It inhibits rheumatoid factor production, antigen presentation, T-cell activation, and proinflammatory cytokine production in rheumatoid arthritis.
Interaction of Mabtas N 500mg Injection with other drugs
Inform your healthcare provider about all the medicines you take, including prescription medications, over-the-counter medications, nutritional and vitamin supplements, and herbal products. In particular, tell your doctor if you are taking medicines for blood pressure or other heart conditions. Certain medications may interact with Mabtas N 500mg Injection and reduce its effectiveness by causing undesirable side effects.
More Information about Mabtas N 500mg Injection
- Store Mabtas N 500mg Injection in the refrigerator (2°C to 8°C)
- Do not freeze
- keep the injection away from the reach of children and pets.
- If you have missed any dosing appointments, inform your doctor and schedule immediately.
How to consume Mabtas N 500mg Injection
It should only be administered by a trained doctor or nurse. Do not self-administer the injection. Before giving Mabtas N 500mg Injection injection, you will be given other medications (pre-medication) to reduce the possible side effects. Your doctor will decide the dose and duration of your treatment based on the disease severity and other factors. It will be given as an intravenous infusion, and you will be monitored carefully for any unwanted side effects.
Safety Advices for Mabtas N 500mg Injection
Pregnancy
Mabtas N 500mg Injection is unsafe to administer in pregnant women because it may affect the fetus. Inform your physician if you are pregnant, suspect pregnancy, or planning to become pregnant. Using an effective birth control method during the treatment and for 12 months after your last dose is necessary.
Breast Feeding
Breastfeeding is not recommended in patients taking Mabtas N 500mg Injection because the medicine passes into the breast milk in small amounts and may harm your baby.
Lungs
It is unknown whether Mabtas N 500mg Injection can be used in patients with lung disorders. Consult your doctor if you have any lung diseases before starting the treatment.
Liver
Whether Mabtas N 500mg Injection can be used in patients with liver impairment is unknown. Consult your doctor if you have or ever had liver disease or hepatitis B infection before starting the treatment. The reactivation of hepatitis viral infection can cause severe liver problems.
Alcohol
Consuming alcohol may affect the effectiveness of Mabtas N 500mg Injection. Stop consuming alcohol if you are taking this medicine.
Driving
Caution is required while driving and operating machinery when you take Mabtas N 500mg Injection because it may cause dizziness, sleepiness, and tiredness and risk of falling.
Side Effects of Mabtas N 500mg Injection
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.
Common:
- Swelling in the face and body
- Diarrhea and nausea
- Itchy skin
- Anemia
- Muscle spasm
- Headache
- Urinary tract infection
- fever, chills, and shivering
- Inflammation of nasal cavities
- Cough, sore throat
- Loss of hair
Serious:
- Increased or decreased blood pressure
- Chest pain
- Hypersensitivity reactions
- Hepatitis B viral infection
- Memory loss, trouble thinking, difficulty in walking
Word of Advice
Avoid vaccines before and during the therapy. Inform your physician if you have been vaccinated recently because Mabtas N 500mg Injection may cause drug-induced immunosuppression. Report to your doctor immediately if you face any symptoms like chest pain, breathing difficulties, stomach pain, and skin reactions. There is limited information available on the safety of this medicine in renal failure patients; inform your physician if you have kidney disease. Vaccination with live virus vaccines is not recommended before or during the treatment for patients with rheumatoid arthritis. Inform your healthcare professional if you have any active infection during the treatment.
FAQs
Q 1. What are the special precautions I should be aware of before starting treatment with Mabtas N 500mg Injection?
Inform your doctor about your pre-existing conditions (heart, kidney, liver, hepatitis B, or lung disease) and vaccination history. It is necessary to consult a doctor if you are taking medicines for blood pressure.
Q 2. What are Mabtas N 500mg Injection infusion-related reactions?
Infusion reactions occur during or within 24 hours after administering Mabtas N 500mg Injection injection. The symptoms are fever, chills, cough, itchy skin, nausea, vomity, flushing, increased heart rate, and discomfort in the throat. Inform your physician immediately if you face any infusion-related reaction.
Q 3. What will be the most important thing to monitor during Mabtas N 500mg Injection infusion?
Your healthcare professional will monitor you carefully for the unwanted side effects that occur during the Mabtas N 500mg Injection infusion. You will be monitored for heart failure, increased blood pressure, or breathing failure.
Fact Box of Mabtas N 500mg Injection
Molecule name: Rituximab | Therapeutic class: 1. Antineoplastics 2. DMARDs |
Pharmacological class: Anti-CD20 monoclonal antibodies | Indications:
|
References
- HIGHLIGHTS OF PRESCRIBING INFORMATION. (2021). Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5464lbl.pdf [Accessed 9 Mar. 2023].
- ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. (2020). Available at: https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf [Accessed 9 Mar. 2023].
- Ahmed A. Negm & Daniel E. Furst, Nonsteroidal Anti-Inflammatory Drugs, Disease-Modifying Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout, Lange's Basic & Clinical Pharmacology, 14th Edition, 2018, 642-666
Disclaimer
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
